<?xml version='1.0' encoding='utf-8'?>
<document id="25450725"><sentence text="Human pharmacokinetic profiling of the dipeptidyl peptidase-IV inhibitor teneligliptin using physiologically based pharmacokinetic modeling." /><sentence text="Teneligliptin is a type 2 diabetes drug that has an inhibitory effect on dipeptidyl peptidase-4"><entity charOffset="0-13" id="DDI-PubMed.25450725.s2.e0" text="Teneligliptin" /></sentence><sentence text=" The aim of this study was to establish a physiologically based pharmacokinetic (PBPK) model to elucidate in detail the pharmacokinetics of teneligliptin"><entity charOffset="140-153" id="DDI-PubMed.25450725.s3.e0" text="teneligliptin" /></sentence><sentence text=" A PBPK model of teneligliptin was developed using the population-based Simcyp simulator incorporating the results of in vitro and in vivo studies"><entity charOffset="17-30" id="DDI-PubMed.25450725.s4.e0" text="teneligliptin" /></sentence><sentence text=" Model validation was conducted by comparison of simulated teneligliptin plasma concentrations with those from clinical trials"><entity charOffset="59-72" id="DDI-PubMed.25450725.s5.e0" text="teneligliptin" /></sentence><sentence text=" Using the PBPK model, predicted drug-drug interactions with concomitant medication were examined" /><sentence text=" The robustness of the PBPK model was demonstrated by the accurate simulation of clinically measured plasma concentrations of teneligliptin after oral administration in different ethnic groups, in subjects belonging to different age groups and in patients with kidney or liver impairment; none of these factors were incorporated during model development"><entity charOffset="126-139" id="DDI-PubMed.25450725.s7.e0" text="teneligliptin" /></sentence><sentence text=" The fraction absorbed and intestinal availability of teneligliptin predicted by the model were 0"><entity charOffset="54-67" id="DDI-PubMed.25450725.s8.e0" text="teneligliptin" /></sentence><sentence text="62 and 0" /><sentence text="99, respectively" /><sentence text=" The predicted ratios of areas under the time-concentration curves (AUCs) in patients with moderate and severe renal impairment who were concomitantly administered ketoconazole, a potent inhibitor of P450 3A4, were, respectively, 2"><entity charOffset="164-176" id="DDI-PubMed.25450725.s11.e0" text="ketoconazole" /></sentence><sentence text="1- and 2" /><sentence text="2-fold those in healthy adults who were given teneligliptin alone" /><sentence text=" A robust PBPK model reflecting the pharmacokinetic properties of teneligliptin was constructed"><entity charOffset="66-79" id="DDI-PubMed.25450725.s14.e0" text="teneligliptin" /></sentence><sentence text=" The final optimized PBPK model enabled us to elucidate in detail the factors affecting the pharmacokinetics of teneligliptin and to predict changes in exposure in drug-drug interactions or in specific populations"><entity charOffset="112-125" id="DDI-PubMed.25450725.s15.e0" text="teneligliptin" /></sentence><sentence text="" /></document>